Triggered from Tapandegan
Hakiman Shargh Research Company and the Shahid Meisami Group
Recent credible information indicates that Iran has been actively involved in developing chemical weapons, specifically anesthetic agents designed for incapacitation. Two key organizations implicated in these activities are the Hakiman Shargh Research Company and the Shahid Meisami Group, both of which have been sanctioned by the United States for their involvement in chemical weapons research and development.
Hakiman Shargh Research Company
The U.S. Department of State imposed sanctions on Hakiman Shargh Research Company in July 2024, citing its role in Iran’s chemical weapons program. The company, based in Isfahan, was designated for engaging in activities that materially contribute to the proliferation of weapons of mass destruction by Iran. This action underscores concerns about Iran’s non-compliance with the Chemical Weapons Convention (CWC), particularly regarding the development of pharmaceutical-based agents for chemical weapons.
Shahid Meisami Group
The Shahid Meisami Group, also known as the Shahid Meisami Research Complex, is a chemical engineering and research entity affiliated with Iran’s defense industries. In December 2020, the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC) designated the group and its director for their involvement in chemical weapons research. The organization is subordinate to the Iranian Organization of Defensive Innovation and Research (SPND) and has been responsible for projects costing millions of U.S. dollars. These projects include testing and producing chemical agents optimized for effectiveness and toxicity as incapacitation agents.
Development of Anesthetic Grenades: “Fadak 110”
Reports suggest that the Shahid Meisami Group, in collaboration with entities like the Hakiman Shargh Research Company, has been involved in developing chemical weapons in the form of anesthetic grenades, notably the “Fadak 110.” These grenades are designed to disperse incapacitating agents, rendering individuals unconscious without causing permanent harm. Such weapons could be employed for crowd control or tactical operations where lethal force is undesirable.
Key Personnel Involved
Ali Pourasad: Identified as the initial head of the Shahid Meisami Group during the development of the Fadak 110 project.
Mehran Babri: Succeeded Pourasad and is the current head of the group. Prior to this role, Babri worked at Iran’s Defense Chemical Research Lab.
Reza Bazshushtari: Served as the project supervisor for the development of the Fadak 110 grenade.
Implications and Concerns
The development of anesthetic grenades like the Fadak 110 raises significant ethical and security concerns. While such weapons are intended for non-lethal incapacitation, their misuse or accidental deployment could lead to unintended casualties. Moreover, the proliferation of chemical incapacitating agents poses a threat to global security, especially if these weapons fall into the hands of non-state actors or are used in violation of international law.
The international community continues to monitor Iran’s activities related to chemical weapons development. The imposition of sanctions on entities like the Hakiman Shargh Research Company and the Shahid Meisami Group reflects ongoing efforts to deter the proliferation of weapons of mass destruction and ensure compliance with global non-proliferation norms.
Credible information from multiple independent sources confirms that Iran, through organizations such as the Hakiman Shargh Research Company and the Shahid Meisami Group, has been actively developing chemical weapons, including anesthetic grenades like the Fadak 110. These developments underscore the importance of vigilant international oversight and enforcement of non-proliferation agreements to prevent the misuse of such technologies.
